# TENNESSEE GENERAL ASSEMBLY FISCAL REVIEW COMMITTEE



# FISCAL NOTE

HB 2367 – SB 2638

February 12, 2024

**SUMMARY OF BILL:** Prohibits an individual, entity, or organization to broadcast, display, or disseminate pharmaceutical advertisements in this state. Establishes a violation of such is an unfair and deceptive act or practice under the *Consumer Protection Act of 1977*. Establishes the Attorney General and Reporter (AG) has investigative and enforcement authority to bring actions for an alleged violation. Prohibits costs of any kind or nature from being taxed against the AG or the state in actions commenced related to such violations.

#### **FISCAL IMPACT:**

#### NOT SIGNIFICANT

### **Assumptions:**

- Any increase in the number of complaints handled by the AG is estimated to be not significant and can be handled by existing staff during normal work hours.
- Committing an unfair or deceptive practice under the *Consumer Protection Act of 1977* is a Class B misdemeanor offense.
- There will not be a sufficient number of prosecutions for state or local government to experience any significant increase in revenue or expenditures.
- Any additional AG duties resulting from the proposed legislation will be absorbed using existing resources.
- Any additional workload on the courts, as a result of this legislation, can be accommodated within existing resources and personnel.
- Based on the Fiscal Review Committee's 2008 study and the Administrative Office of the Courts' 2012 study on collection of court costs, fees, and fines, collection in criminal cases is insignificant. The proposed legislation will not significantly change state or local revenue.

## **IMPACT TO COMMERCE:**

#### **NOT SIGNIFICANT**

#### Assumption:

• The net impact to commerce or jobs in Tennessee is estimated to be not significant.

# **CERTIFICATION:**

The information contained herein is true and correct to the best of my knowledge.

Krista Lee Carsner, Executive Director

Kista La Caroner

/vh